Ivacaftor therapy in siblings with cystic fibrosis-the potential implications of Itraconazole in dosage and efficacy

Pulm Pharmacol Ther. 2015 Apr:31:49-50. doi: 10.1016/j.pupt.2015.01.003. Epub 2015 Feb 4.

Authors

M J Harrison¹, N J Ronan¹, K A Khan¹, G O'Callaghan¹, D M Murphy¹, B J Plant²

Affiliations

¹ Cork Adult Cystic Fibrosis Centre, Dept. of Medicine, Cork University Hospital/University College Cork, Wilton, Cork, Ireland.
² Cork Adult Cystic Fibrosis Centre, Dept. of Medicine, Cork University Hospital/University College Cork, Wilton, Cork, Ireland. Electronic address: [email protected].

PMID: 25660163
DOI: 10.1016/j.pupt.2015.01.003

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aminophenols / administration & dosage*
Aminophenols / pharmacokinetics*
Antifungal Agents / administration & dosage
Antifungal Agents / pharmacology*
Cystic Fibrosis / drug therapy*
Cystic Fibrosis / genetics
Cytochrome P-450 CYP3A Inhibitors / pharmacology
Dose-Response Relationship, Drug
Drug Antagonism
Enzyme Inhibitors
Humans
Itraconazole / administration & dosage
Itraconazole / pharmacology*
Male
Mutation
Quinolones / administration & dosage*
Quinolones / pharmacokinetics*
Siblings*

Substances

Aminophenols
Antifungal Agents
Cytochrome P-450 CYP3A Inhibitors
Enzyme Inhibitors
Quinolones
ivacaftor
Itraconazole